Pembrolizumab Meets Primary End Point of OS in Advanced Pretreat Hepatocellular Carcinoma


Patients with advanced hepatocellular carcinoma who received prior treatment with sorafenib appear to benefit from treatment with pembrolizumab and best supportive care.

Pembrolizumab (Keytruda) plus best supportive care resulted in a notable survival benefit in a population of Asian patients with advanced hepatocellular carcinoma (HCC) who received prior treatment with sorafenib (Nexavar), according to findings from the phase 3 KEYNOTE-394 trial (NCT03062358).1

Data from the trial indicated that patients who received pembrolizumab and best supportive care experienced a statistically significant improvement in overall survival (OS) vs placebo. Moreover, statistically significant improvements in key secondary end points such as progression-free survival (PFS) and objective response rate were also reported. Findings from the trial will be presented at an upcoming meeting.

“Frequently diagnosed at an advanced stage, [HCC] has one of the highest mortality rates of solid cancers. Despite recent progress, there remains an unmet need for anti–PD-1 monotherapy after sorafenib, where [pembrolizumab] is an established treatment option for patients,” Scot Ebbinghaus, MD, vice president of clinical research at Merck Research Laboratories, said in a press release. “It is very encouraging that [pembrolizumab] significantly improved [OS] in this study, and we look forward to engaging with regulatory authorities as quickly as possible.”

The randomized trial has an estimated enrollment of 454 patients who would receive intravenous pembrolizumab on day 1 of each 3-week cycle for up to 35 cycles plus best supportive care, or intravenous placebo plus best supportive care with the same schedule as the experimental arm.

Eligible patients had an HCC diagnosis confirmed by radiology, histology, or cytology, as well as Barcelona Clinic Liver Cancer stage C or B disease that is not amenable or is refractory to locoregional therapy and is not amenable to a curative approach. Additionally, a life expectancy of 3 or more months and an ECOG performance status of 0 or 1 was required.

Pembrolizumab was previously granted an accelerated approval from the FDA in November 2018 for patients with HCC who received prior treatment with sorafenib.2 The decision was based on results from the phase 3 KEYNOTE-224 trial (NCT02702414), which reported that patients had a complete response rate of 1.0% and a partial response rate of 15.4%.3 Additionally, 45.2% of patients achieved stable disease and 32.7% experienced progressive disease. It was also reported that patients had a disease control rate of 61.5%. Patients had a median PFS of 4.8 months (95% CI, 3.4-6.6) and the median OS was not reached. The 6-month PFS rate was 43.1% and the OS rate was 77.9%.

The most common treatment-related adverse effects (AEs) were fatigue (21.2%) and increased aspartate aminotransferase (12.5%), with grade 3 to 5 AEs occurring in 25% of patients, including 1 death due to ulcerative esophagitis.


  1. Merck announces KEYTRUDA® (pembrolizumab) met primary endpoint of overall survival (OS) in patients with advanced hepatocellular carcinoma previously treated with sorafenib. News release. Merck. September 27, 2021. Accessed September 28, 2021.
  2. FDA grants accelerated approval to pembrolizumab for hepatocellular carcinoma. News release. FDA. November 9, 2018. Accessed September 28, 2021.
  3. Zhu AX, Finn RS, Cattan S, et al. KEYNOTE-224: Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib. J Clin Oncol. 2018;36(suppl 4):209-209. doi:10.1200/JCO.2018.36.4_suppl.209
Related Videos
Rates of obesity appear to correlate with increasing incidence of cancer in young populations, according to Monique Gary, DO, MSc, FACS.
Adding radiation to sorafenib elicited a survival improvement in a group of patients with hepatocellular carcinoma, a type of liver cancer.
Data from a ctDNA analysis of the phase 3 INTRIGUE study indicate that KIT mutational status may be associated with response to certain Tyrosine kinase inhibitors in GIST, according to an expert from the Yale Cancer Center in New Haven, Massachusetts.
Future research into the management of unresectable hepatocellular carcinoma may involve combining local therapies with checkpoint inhibitors like durvalumab and tremelimumab, according to Ghassan K. Abou-Alda, MD.
Patients with unresectable hepatocellular carcinoma who have recurrent disease following surgery or locally advanced diseases who will likely progress on local therapy may have an opportunity to benefit from tremelimumab and durvalumab following its FDA approval, according to Ghassan K. Abou-Alfa, MD.
Ghassan K. Abou-Alfa, MD, discusses the importance of improving access to novel therapies and combinations for patients with hepatocellular carcinoma across the world.
Ghassan K. Abou-Alfa, MD, spoke about the recent approval of tremelimumab plus durvalumab for patients with unresectable hepatocellular carcinoma, based on results from the phase 3 HIMALAYA trial.
Howard A. Burris, MD, highlighted previous findings of the phase 3 TOPAZ-1 trial assessing durvalumab plus gemcitabine and cisplatin vs placebo plus gemcitabine and cisplatin in advanced biliary tract cancer and patient-reported outcomes (PRO)data that were presented at 2022 ASCO.
Shubham Pant, MD discusses key findings from a basket trial examining the use of erdafitinib in patients with gastrointestinal cancers.
Related Content